We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Humanigen Inc (CE) | USOTC:HGEN | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0002 | 0.00 | 01:00:00 |
Delaware
|
77-0557236
|
|
(State or other jurisdiction of
incorporation or organization)
|
(IRS employer identification
number)
|
Large accelerated filer
☐
|
Accelerated filer
☐
|
|
Non-accelerated filer
☐
(Do not check if a smaller reporting company)
|
Smaller reporting company
☒
Emerging growth company
☒
|
Title of Securities
to be
Registered
|
Amount
to be Registered (1) |
Proposed Maximum
Offering Price per Share (2) |
Proposed Maximum
Aggregate Offering Price |
Amount of
Registration Fee |
|||||||||||
|
|||||||||||||||
Common stock, $0.001 par value per share
|
16,050,000
|
$
|
0.45
|
$
|
7,222,500
|
$
|
899
|
Item 3. |
Incorporation of Documents by Reference.
|
(a) |
the Company
’
s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (File No. 001-35798);
|
(b) |
the Company
’
s Current Reports on Form 8-K filed on January 12, 2018, January 29, 2018, February 7, 2018 (as amended by the Current Report on Form 8-K/A, filed on March 13, 2018), February 28, 2018 and March 13, 2018; and
|
(c) |
the description of the Company
’
s common stock contained in the Company
’
s Registration Statement on Form 8-A (File No. 333-35798) filed with the Commission on January 30, 2013 under Section 12(b) of the Exchange Act, as amended by the description contained in the Company’s Current Report on Form 8-K filed on August 7, 2017, and as may be further amended in any future amendments or reports filed for the purpose of updating such description.
|
Item 4. |
Description of Securities
.
|
Item 5. |
Interests of Named Experts and Counsel
.
|
Item 6. |
Indemnification of Directors and Officers
.
|
· |
transaction from which the director derived an improper personal benefit;
|
· |
act or omission not in good faith or that involved intentional misconduct or a knowing violation of law;
|
· |
unlawful payment of dividends or redemption of shares; or
|
· |
breach of the director
’
s duty of loyalty to the corporation or its stockholders.
|
Item 7.
|
Exemption from Registration Claimed
.
|
Item 8. |
Exhibits
.
|
Item 9. |
Undertakings
.
|
Humanigen, Inc.
|
||
|
|
|
|
|
|
By:
|
/s/ Cameron Durrant, M.D., MBA
|
|
Cameron Durrant, M.D., MBA
|
||
Chairman of the Board and Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
/s/ Cameron Durrant, M.D., MBA
|
|
|
|
|
|
Cameron Durrant, M.D., MBA
|
|
Chairman of the Board and Chief Executive Officer
(Principal Executive Officer) |
|
April 18, 2018
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
Greg Jester
|
|
Chief Financial Officer (Principal Financial
Officer, Principal Accounting Officer)
|
|
April 18, 2018
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
Ronald Barliant
|
|
Director
|
|
April 18, 2018
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
Rainer Boehm
|
|
Director
|
|
April 18, 2018
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
Robert G. Savage
|
|
Director
|
|
April 18, 2018
|
|
|
|
|
|
|
|
*
|
|
|
|
|
|
Timothy Morris
|
|
Director
|
|
April 18, 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* By:
|
/s/ Cameron Durrant, M.D., MBA
|
||||
|
Cameron Durrant, M.D., MBA
Attorney-in-Fact |
Exhibit No.
|
Exhibit
|
|
|
|
|
4.1
|
||
|
|
|
5.1
|
||
|
|
|
10.1
|
||
|
|
|
10.2
|
|
|
|
|
|
10.3
|
|
|
10.4
|
||
10.5
|
||
10.6
|
||
23.1
|
||
|
|
|
23.2
|
||
|
|
|
24.1
|
1 Year Humanigen (CE) Chart |
1 Month Humanigen (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions